Mesoblast (MESO) Competitors $15.17 -0.09 (-0.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.14 -0.04 (-0.23%) As of 08/1/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MESO vs. ELAN, RGC, RVMD, GRFS, TGTX, NUVL, CRSP, RYTM, TLX, and AXSMShould you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), CRISPR Therapeutics (CRSP), Rhythm Pharmaceuticals (RYTM), Telix Pharmaceuticals (TLX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Mesoblast vs. Its Competitors Elanco Animal Health Regencell Bioscience Revolution Medicines Grifols TG Therapeutics Nuvalent CRISPR Therapeutics Rhythm Pharmaceuticals Telix Pharmaceuticals Axsome Therapeutics Elanco Animal Health (NYSE:ELAN) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations. Do analysts prefer ELAN or MESO? Elanco Animal Health currently has a consensus target price of $16.17, suggesting a potential upside of 17.15%. Mesoblast has a consensus target price of $18.00, suggesting a potential upside of 18.66%. Given Mesoblast's stronger consensus rating and higher possible upside, analysts clearly believe Mesoblast is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elanco Animal Health 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor ELAN or MESO? In the previous week, Elanco Animal Health had 11 more articles in the media than Mesoblast. MarketBeat recorded 11 mentions for Elanco Animal Health and 0 mentions for Mesoblast. Elanco Animal Health's average media sentiment score of 1.18 beat Mesoblast's score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Overall Sentiment Elanco Animal Health Positive Mesoblast Neutral Is ELAN or MESO more profitable? Elanco Animal Health has a net margin of 8.43% compared to Mesoblast's net margin of 0.00%. Elanco Animal Health's return on equity of 7.54% beat Mesoblast's return on equity.Company Net Margins Return on Equity Return on Assets Elanco Animal Health8.43% 7.54% 3.57% Mesoblast N/A N/A N/A Which has more volatility and risk, ELAN or MESO? Elanco Animal Health has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500. Which has stronger valuation & earnings, ELAN or MESO? Elanco Animal Health has higher revenue and earnings than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElanco Animal Health$4.44B1.54$338M$0.7418.65Mesoblast$5.90M329.11-$87.96MN/AN/A Do insiders and institutionals hold more shares of ELAN or MESO? 97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 0.9% of Elanco Animal Health shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryElanco Animal Health beats Mesoblast on 9 of the 14 factors compared between the two stocks. Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MESO vs. The Competition Export to ExcelMetricMesoblastMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.95B$2.99B$5.48B$9.53BDividend YieldN/A2.43%4.73%4.09%P/E RatioN/A17.7428.8623.83Price / Sales329.11178.71371.4466.13Price / CashN/A41.9535.4557.96Price / Book3.608.508.265.54Net Income-$87.96M-$55.06M$3.25B$259.28M7 Day Performance-7.27%-3.99%-3.73%-4.67%1 Month Performance39.69%9.58%4.28%4.38%1 Year Performance140.03%6.70%25.85%17.90% Mesoblast Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MESOMesoblast0.7699 of 5 stars$15.17-0.6%$18.00+18.7%+141.2%$1.95B$5.90M0.0080ELANElanco Animal Health3.8124 of 5 stars$14.67-0.8%$16.00+9.1%+5.9%$7.28B$4.44B19.829,000Upcoming EarningsRGCRegencell Bioscience0.0501 of 5 stars$14.40-0.7%N/AN/A$7.17BN/A0.0010Positive NewsRVMDRevolution Medicines4.4789 of 5 stars$38.42+0.3%$68.91+79.4%-19.1%$7.16B$11.58M-9.61250News CoveragePositive NewsUpcoming EarningsGRFSGrifols3.2462 of 5 stars$10.00+0.6%$10.30+3.0%+41.1%$6.83B$7.21B8.5523,822Dividend AnnouncementTGTXTG Therapeutics4.0694 of 5 stars$37.42-1.3%$43.80+17.0%+85.0%$5.94B$329M155.92290Positive NewsUpcoming EarningsNUVLNuvalent3.2258 of 5 stars$82.46-1.1%$119.60+45.0%+2.0%$5.92BN/A-18.7840Positive NewsCRSPCRISPR Therapeutics2.8172 of 5 stars$65.33+0.3%$71.75+9.8%+2.3%$5.64B$37.31M-14.45460Upcoming EarningsAnalyst RevisionHigh Trading VolumeRYTMRhythm Pharmaceuticals3.5477 of 5 stars$88.63-0.6%$91.93+3.7%+88.5%$5.64B$130.13M-31.54140Upcoming EarningsInsider TradeTLXTelix PharmaceuticalsN/A$16.50+1.7%$22.33+35.4%N/A$5.58B$516.72M0.00N/AGap DownHigh Trading VolumeAXSMAxsome Therapeutics4.8158 of 5 stars$109.68-1.8%$172.33+57.1%+19.8%$5.40B$385.69M-19.01380Positive NewsUpcoming Earnings Related Companies and Tools Related Companies ELAN Competitors RGC Competitors RVMD Competitors GRFS Competitors TGTX Competitors NUVL Competitors CRSP Competitors RYTM Competitors TLX Competitors AXSM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MESO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
